Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma.
Meertens M, Giraud EL, Hassan E, Zielhuis SWJ, Snels TT, Desar IME, Walraven JEW, Wilgenhof S, van Thienen JV, de Boer JP, Steeghs N, van Erp NP, Huitema ADR. Meertens M, et al. Among authors: wilgenhof s. Cancer Chemother Pharmacol. 2025 Jan 17;95(1):25. doi: 10.1007/s00280-024-04746-5. Cancer Chemother Pharmacol. 2025. PMID: 39820703
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.
Borgers JSW, Lenkala D, Kohler V, Jackson EK, Linssen MD, Hymson S, McCarthy B, O'Reilly Cosgrove E, Balogh KN, Esaulova E, Starr K, Ware Y, Klobuch S, Sciuto T, Chen X, Mahimkar G, Sheen JHF, Ramesh S, Wilgenhof S, van Thienen JV, Scheiner KC, Jedema I, Rooney M, Dong JZ, Srouji JR, Juneja VR, Arieta CM, Nuijen B, Gottstein C, Finney OC, Manson K, Nijenhuis CM, Gaynor RB, DeMario M, Haanen JB, van Buuren MM. Borgers JSW, et al. Among authors: wilgenhof s. Nat Med. 2025 Jan 3. doi: 10.1038/s41591-024-03418-4. Online ahead of print. Nat Med. 2025. PMID: 39753970
Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.
Curigliano G, Curigliano H, Mach N, Doi T, Tai D, Forde PM, Sarantopoulos J, Bedard PL, Lin CC, Hodi FS, Wilgenhof S, Santoro A, Sabatos-Peyton CA, Longmire TA, Xyrafas A, Sun H, Gutzwiller S, Manenti L, Naing A. Curigliano G, et al. Among authors: wilgenhof s. Clin Cancer Res. 2024 Sep 3;30(17):3957. doi: 10.1158/1078-0432.CCR-24-2131. Clin Cancer Res. 2024. PMID: 39224022 No abstract available.
Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study.
Lin CC, Curigliano G, Santoro A, Kim DW, Tai D, Hodi FS, Wilgenhof S, Doi T, Sabatos-Peyton C, Szpakowski S, Chitnis S, Xyrafas A, Gutzwiller S, Pastore A, Mach N. Lin CC, et al. Among authors: wilgenhof s. BMJ Open. 2024 Aug 29;14(8):e079132. doi: 10.1136/bmjopen-2023-079132. BMJ Open. 2024. PMID: 39209782 Free PMC article. Clinical Trial.
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, Hoeijmakers LL, Saw RPM, Lijnsvelt JM, Maher NG, Pulleman SM, Gonzalez M, Torres Acosta A, van Houdt WJ, Lo SN, Kuijpers AMJ, Spillane A, Klop WMC, Pennington TE, Zuur CL, Shannon KF, Seinstra BA, Rawson RV, Haanen JBAG, Ch'ng S, Naipal KAT, Stretch J, van Thienen JV, Rtshiladze MA, Wilgenhof S, Kapoor R, Meerveld-Eggink A, Grijpink-Ongering LG, van Akkooi ACJ, Reijers ILM, Gyorki DE, Grünhagen DJ, Speetjens FM, Vliek SB, Placzke J, Spain L, Stassen RC, Amini-Adle M, Lebbé C, Faries MB, Robert C, Ascierto PA, van Rijn R, van den Berkmortel FWPJ, Piersma D, van der Westhuizen A, Vreugdenhil G, Aarts MJB, Stevense-den Boer MAM, Atkinson V, Khattak M, Andrews MC, van den Eertwegh AJM, Boers-Sonderen MJ, Hospers GAP, Carlino MS, de Groot JB, Kapiteijn E, Suijkerbuijk KPM, Rutkowski P, Sandhu S, van der Veldt AAM, Long GV. Blank CU, et al. Among authors: wilgenhof s. N Engl J Med. 2024 Nov 7;391(18):1696-1708. doi: 10.1056/NEJMoa2402604. Epub 2024 Jun 2. N Engl J Med. 2024. PMID: 38828984 Clinical Trial.
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.
Embaby A, Huijberts SCFA, Wang L, Leite de Oliveira R, Rosing H, Nuijen B, Sanders J, Hofland I, van Steenis C, Kluin RJC, Lieftink C, Smith CG, Blank CU, van Thienen JV, Haanen JBAG, Steeghs N, Opdam FL, Beijnen JH, Huitema ADR, Bernards R, Schellens JHM, Wilgenhof S. Embaby A, et al. Among authors: wilgenhof s. Clin Cancer Res. 2024 Aug 1;30(15):3157-3166. doi: 10.1158/1078-0432.CCR-23-3171. Clin Cancer Res. 2024. PMID: 38739109
Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy.
Egeler M, Lai-Kwon J, Tissier R, Fraterman I, Kuijpers A, Van Houdt W, Wilgenhof S, Rao A, Sandhu S, Lee R, Eriksson H, van Leeuwen M, de Ligt K, van Akkooi A, van de Poll-Franse L. Egeler M, et al. Among authors: wilgenhof s. Eur J Cancer. 2024 Mar;200:113601. doi: 10.1016/j.ejca.2024.113601. Epub 2024 Feb 4. Eur J Cancer. 2024. PMID: 38340383
An eHealth App (CAPABLE) Providing Symptom Monitoring, Well-Being Interventions, and Educational Material for Patients With Melanoma Treated With Immune Checkpoint Inhibitors: Protocol for an Exploratory Intervention Trial.
Fraterman I, Wollersheim BM, Tibollo V, Glaser SLC, Medlock S, Cornet R, Gabetta M, Gisko V, Barkan E, di Flora N, Glasspool D, Kogan A, Lanzola G, Leizer R, Mallo H, Ottaviano M, Peleg M, van de Poll-Franse LV, Veggiotti N, Śniatała K, Wilk S, Parimbelli E, Quaglini S, Rizzo M, Locati LD, Boekhout A, Sacchi L, Wilgenhof S. Fraterman I, et al. Among authors: wilgenhof s. JMIR Res Protoc. 2023 Oct 11;12:e49252. doi: 10.2196/49252. JMIR Res Protoc. 2023. PMID: 37819691 Free PMC article.
Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?
Fransen van de Putte EE, van den Brink L, Mansour MA, van der Mijn JC, Wilgenhof S, van Thienen JV, Haanen JBAG, Boleti E, Powles T, Zondervan PJ, Graafland NM, Bex A. Fransen van de Putte EE, et al. Among authors: wilgenhof s. Eur Urol Open Sci. 2023 Aug 4;55:15-22. doi: 10.1016/j.euros.2023.07.002. eCollection 2023 Sep. Eur Urol Open Sci. 2023. PMID: 37693729 Free PMC article.
61 results